Variability in the Definition and Reporting of Adverse Events in Suicide Prevention Trials: An Examination of the Issues and a Proposed Solution

被引:6
作者
Oquendo, Maria A. [1 ]
Feldman, Sarah [1 ]
Silverman, Emily [1 ]
Currier, Dianne [2 ]
Brown, Gregory K. [3 ]
Chen, Donna [4 ]
Chiapella, Page [5 ]
Fischbach, Ruth [1 ]
Gould, Madelyn [1 ]
Stanley, Barbara [1 ]
Strauss, David [1 ]
Zelazny, Jamie [6 ]
Pearson, Jane [7 ]
机构
[1] New York State Psychiat Inst & Hosp, New York, NY 10032 USA
[2] Columbia Univ, Dept Psychiat, New York, NY USA
[3] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
[4] Univ Virginia, Ctr Biomed Eth & Humanities, Charlottesville, VA USA
[5] NIAAA, Bethesda, MD USA
[6] Univ Pittsburgh, Pittsburgh, PA USA
[7] NIMH, Bethesda, MD 20892 USA
关键词
Adverse Events; safety; Serious Adverse Events; study evaluation; suicide research; TOWER-OF-BABEL; CLINICAL-TRIALS; SAFETY; INTERVENTION; NOMENCLATURE; MULTICENTER; IMPROVEMENT; BEHAVIOR; LESSONS; CARE;
D O I
10.1080/13811118.2011.541146
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Adverse events (AEs) and serious adverse events (SAEs) are important outcomes of any intervention study yet are under-researched. Vague and variable definitions and substantial underreporting make comparisons of risk between studies difficult and evaluation of the safety of a particular intervention almost impossible. These realities may deter researchers from studying at-risk populations. Suicidal behavior is an adverse event in any study, and potentially a very serious one. Thus the issues of reporting and definition are particularly salient for researchers who work with populations at risk for suicidal behavior, especially when the suicidal behavior is the outcome of interest. We conducted a qualitative study with experienced suicide researchers and intervention experts to delineate the issues related to reporting serious adverse events faced by investigators conducting trials in suicide prevention. Participants from multiple sites were interviewed by phone, interviews transcribed and coded for definition and reporting issues and suggested solutions. A narrative synthesis was prepared and validated by all participants. Participants highlighted the difficulties in defining AEs and SAEs and stressed the importance and complexity of ensuring the AE was related to the study and reported properly, and were in agreement about the consequences of AEs to both institutions and individuals. Participants identified the need for the development of clear and consistent AE definitions and reporting requirements. Clear and consistently applied definitions of adverse and serious adverse events and reporting requirements would enhance the comparability of intervention studies in suicidal populations.
引用
收藏
页码:29 / 42
页数:14
相关论文
共 50 条
  • [41] The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members
    Maillet, D.
    Blay, J. Y.
    You, B.
    Rachdi, A.
    Gan, H. K.
    Peron, J.
    ANNALS OF ONCOLOGY, 2016, 27 (01) : 192 - 198
  • [42] Serious adverse events reporting in recent randomised clinical trials in intensive care medicine - A methodological study protocol
    Jensen, Marie Qvist
    Munch, Marie Warrer
    Granholm, Anders
    Moller, Morten Hylander
    Bahrenkova, Marina
    Perner, Anders
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2024, 68 (10) : 1581 - 1587
  • [43] Evaluating the reporting of adverse events in controlled clinical trials conducted in 2010-2015 on migraine drug treatments
    Tfelt-Hansen, Peer
    Lindqvist, Janus Kaufmann
    Thien Phu Do
    CEPHALALGIA, 2018, 38 (12) : 1885 - 1895
  • [44] Predictive factors for reporting adverse events following spinal manipulation in randomized clinical trials - secondary analysis of a systematic review
    Gorrell, Lindsay M.
    Brown, Benjamin
    Lystad, Reidar P.
    Engel, Roger M.
    MUSCULOSKELETAL SCIENCE AND PRACTICE, 2017, 30 : 34 - 41
  • [45] Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events
    Almeida, Luis
    Kashdan, Todd B.
    Nunes, Teresa
    Coelho, Rui
    Albino-Teixeira, Antonio
    Soares-da-Silva, Patricio
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (06) : 575 - 582
  • [46] Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events
    Luis Almeida
    Todd B. Kashdan
    Teresa Nunes
    Rui Coelho
    António Albino-Teixeira
    Patrício Soares-da-Silva
    European Journal of Clinical Pharmacology, 2008, 64 : 575 - 582
  • [47] Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice
    Campbell, Rachel
    King, Madeleine T.
    Stockler, Martin R.
    Lee, Yeh Chen
    Roncolato, Felicia T.
    Friedlander, Michael L.
    PATIENT-RELATED OUTCOME MEASURES, 2023, 14 : 111 - 126
  • [48] Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative
    Reeve, Bryce B.
    McFatrich, Molly
    Pinheiro, Laura C.
    Weaver, Meaghann S.
    Sung, Lillian
    Withycombe, Janice S.
    Baker, Justin N.
    Mack, JenniferW.
    Waldron, Mia K.
    Gibson, Deborah
    Tomlinson, Deborah
    Freyer, David R.
    Mowbray, Catriona
    Jacobs, Shana
    Palma, Diana
    Martens, Christa E.
    Gold, Stuart H.
    Jackson, Kathryn D.
    Hinds, Pamela S.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (03)
  • [49] The Feasibility, Perceived Satisfaction, and Value of Using Synchronous Webinars to Educate Clinical Research Professionals on Reporting Adverse Events in Clinical Trials: A Report From the Children's Oncology Group
    Borgerson, Dawn
    Dino, Jennifer
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2012, 29 (06) : 316 - 322
  • [50] Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials
    Wang, Xinyi
    Li, Jingen
    Wang, Tongxin
    Zhang, Zihao
    Li, Qiuyi
    Ma, Dan
    Chen, Zhuo
    Ju, Jianqing
    Xu, Hao
    Chen, Keji
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9